US Edition
Wave Life Sciences Shares Plunge as Data for High Dose of Obesity Drug ...
Shares dropped nearly 50% after Phase 1 data showed body composition benefits but modest weight loss and weaker results at higher doses, prompting analyst price target cuts.
- Wave Life Sciences shares fell nearly 50% to $6.20 on Thursday after releasing mixed Phase 1 INLIGHT obesity trial data for its drug candidate WVE-007.
- While the 240 mg dose showed "clinically meaningful" visceral fat reduction, the 400 mg dose failed to meet company expectations, disappointing investors seeking robust efficacy.
- BofA and Wells Fargo cut price targets to $21 and $13, citing insufficient monotherapy data and reduced conviction in the liver Activin E knockdown mechanism.
- Trading volume surged about 1,153% above the three-month average as shareholders reacted to the disappointing monotherapy signal, driving the stock to its lowest level in over a year.
- Wave plans a Phase 2a trial in higher-BMI patients during the second quarter of 2026 to demonstrate efficacy in a population more representative of the obesity market.
13 Articles
13 Articles
Wave Life Sciences Slips as Obesity Data Fails to Convince
Quick Read Wave Life Sciences (WVE) shares fell nearly 50% to $6.20 after BofA and Wells Fargo cut price targets to $21 and $13 respectively, citing insufficient data for WVE-007 as a standalone obesity treatment and reduced conviction in the liver Activin E knockdown mechanism. The INLIGHT trial showed 14.3% placebo-adjusted visceral fat reduction with preserved lean muscle, but the Phase 1 cohort included lower-BMI patients than typical obes…
Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints
Wave Life Sciences (NASDAQ:WVE), developer of RNA medicines for rare genetic diseases, closed Thursday at $6.20, down 49.59% for the session. The stock sank after disappointing higher-dose WVE-007 obesity data underperformed the lower dose. Trading volume reached 49.9 million shares, coming in about 1,153% above its three-month average of 4 million shares. Wave Life Sciences IPO'd in 2015 and has fallen 61% since going public.How the markets mov…
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
